Yi Zhong

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Combination Therapy

Peritoneal Dialysis

Duchenne Muscular Dystrophy

Electronic Health Record

Top Venues

Journal of comparative effectiveness research

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Joel Iff, Nicolae Done, Edward Tuttle, Yi Zhong, Fangzhou Wei, Basil T Darras, Craig M McDonald, Eugenio Mercuri, Francesco Muntoni
Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls. Muscle & nerve 70 (1) (2024)
Joel Iff, Nicolae Done, Edward Tuttle, Yi Zhong, Fangzhou Wei, Basil T Darras, Craig M McDonald, Eugenio Mercuri, Francesco Muntoni
Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls. Muscle & nerve 70 (1) (2024)
Joel Iff, Nicolae Done, Edward Tuttle, Yi Zhong, Fangzhou Wei, Basil T Darras, Craig M McDonald, Eugenio Mercuri, Francesco Muntoni
Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls. Muscle & nerve (2024)
Joel Iff, Yi Zhong, Edward Tuttle, Deepshekhar Gupta, Xander Paul, Erik K Henricson
Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA. Journal of comparative effectiveness research (2023)
Joel Iff, Yi Zhong, Deepshekhar Gupta, Xander Paul, Edward Tuttle, Erik Henricson, Rachel Schrader, null null
Disease Progression Stages and Burden in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Supplemented by Electronic Medical Records. Advances in therapy 39 (6) (2022)
Joel Iff, Charles Gerrits, Yi Zhong, Edward Tuttle, Erica Birk, Yeya Zheng, Xander Paul, Erik K Henricson, Craig M McDonald, null null
Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy. Muscle & nerve 66 (3) (2022)